Rx/Reimbursement Adult Incontinence in the US

Rx/reimbursement adult incontinence in the US maintained stable volume and current value growth in 2024. Nevertheless, post-pandemic, Medicaid disenrollment was underway, after three years of continuous enrolment. During the pandemic, states operated under a policy of continuous enrolment, which officially ended in March 2023, with some states winding down disenrollment until June 2024. According to the nonprofit organisation Kaiser Family Foundation (KFF), 23 million people have been disenrolle...

Euromonitor International's Rx/Reimbursement adult incontinence in USA report offers a comprehensive guide to the size and shape of the market at a national level. It provides the latest retail sales data 2020-2024, allowing you to identify the sectors driving growth. It identifies the leading companies, the leading brands and offers strategic analysis of key factors influencing the market – be they new product developments, distribution or pricing issues. Forecasts to 2029 illustrate how the market is set to change.

Data coverage: market sizes (historic and forecasts), company shares, brand shares and distribution data.

Why buy this report?
* Get a detailed picture of the Rx/Reimbursement adult incontinence market;
* Pinpoint growth sectors and identify factors driving change;
* Understand the competitive environment, the market’s major players and leading brands;
* Use five-year forecasts to assess how the market is predicted to develop.